National and Kapodistrian University of Athens
Σακχαρώδης διαβήτης τύπου 2 και κατάθλιψη
Abstract
dc:descriptionDepression is a comorbid condition in patients with Type 2 Diabetes mellitus (T2DM). Ghrelin has an important role in glucose tolerance and insulin secretion and through its effect on synaptic plasticity can play a probable part in depression. S100B, a glia derived protein, is linked to depression and has been suggested as a biomarker for depression outcomes in several populations. However, to date there is no data about ghrelin and S100B levels depression in patients with T2DM concerning co- occurring depression. Objective: We hypothesized that ghrelin levels are higher in patients with T2DM and recently diagnosed, drug-free depressive symptoms compared to those without depression and that S100B serum levels are increased in patients with T2DM and recently diagnosed depression and as a result S100B could be used as a biomarker for the diagnosis of depression in T2DM. Methods: Overall 52 patients (62 ± 12 years, female 66, 7%) with no history of depression deriving from the Diabetes out-patient clinic of our University Hospital underwent a one-to-one interview with a psychiatrist and filled the self-assessment Zung questionnaire for depression. Serum Ghrelin and S00B levels were compared between 30 (63±12 years, female 66, 7%) diabetic patients without depressive symptoms vs. 22 patients (62 ±12 years, female 68, 2%) with T2DM and depressive symptoms. Results: Ghrelin levels were higher in non-depressive diabetics vs. depressive diabetics [22.7(22.4-23.4 pg/ml) vs. 22.3 (22.3-22.6 pg/ml), respectively, p=0.03]. Also a higher than median (≥ 22.7 pg/ml) ghrelin level was reversely associated with depression [odds ratio (OR) 0.257 (95% CI 0.075 – 0.879), p = 0.030] even after adjustment for age gender and body mass index [odds ratio (OR) 0.203 (95% CI 0.052- 0.794), =0.022]. There was no difference between patients with T2DM without depressive symptoms vs. diabetic patients suffering from depressive symptoms in leptin levels [14797 (7632- 189245) pg/ml vs. 11211 (6199- 31643) pg/ml, respectively, p=0.350] and TNFα levels (5,3±2 pg/ml vs. 6,6±2,6 pg/ml, respectively, p=0.058). Furthermore, there was no difference in S100B serum levels between patients with T2DM without depressive symptoms vs. diabetic patients suffering from depressive symptoms [2.1 (1.9-10.9) pg/ml vs. 2.4 (1.9-14.8) pg/ml, p=0. 637]. Moreover, linear regression analysis did not show any association between lnS100B values and depressive symptoms (β = 0.084, 95% CI 0.470-0.871, and p=0.552), Zung self-assessment scale score (β = 0.048, 95% CI -0.024-0.033, and p=0.738), and other patients’ characteristics. Conclusions: In patients with T2DM no correlation was found between S100B serum levels and newly detected mild depressive symptoms. There was a reverse association of high ghrelin serum levels with depressive symptoms. These results could be attributed to a disruption in neuroplasticity or in the reward system. The brain biochemistry pathways of depression in T2DM warrant further investigation in a larger scale population.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Katsanou, Panagiota
- Κατσάνου, Παναγιώτα
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46945